Lilly’s next-gen obesity drug shows weight loss potential but safety signals need more data

Lilly’s obesity drug retatrutide, which previously showed rapid weight loss and diabetes benefits, yielded new safety data at the ADA meeting and in Lancet: in TRANSCEND-T2D-1, 7 of 403 participants on retatrutide had arrhythmias and 3 had major cardiovascular events versus none on placebo, a small event count that experts say is insufficient to draw firm cardiovascular risk conclusions.